Isolate confirmation
====================

Presumptive *Shigella*isolates were confirmed using conventional biochemical tests \[[@B14]\]. Serotyping was done for *S. flexneri*and phagetyping was done for *S*. *sonnei*. Serotyping was performed using commercially available antisera (Denka Seiken USA Inc., Campbell, CA) for *S .flexneri*and the following serotypes (STs) were determined: 1-4, 6, SH-101, SH-104, and variants × or y \[[@B14]\]. Phage typing was performed on *S. sonnei*isolates following standard procedures at the National Microbiology Laboratory in Winnipeg, Manitoba \[[@B15]\]. For 2002 and 2003, there were representative but fewer numbers of isolates were available for testing. For example, in 2002 and 2003, only 24% and 58% of representative isolates were available respectively. From 2004-2007, representative isolates for each case of infection were available for susceptibility testing: 2004 (100%), 2005 (100%), 2006 (89%), 2007 (91%).

Susceptibility testing
======================

Susceptibility testing was performed using Sensititre panels (Trek Diagnostic Systems, Cleveland, OH) against the following antimicrobial agents:

• amikacin (AMI)

• amoxicillin/clavulanic acid (AMC)

• ampicillin (AMP)

• cefoxitin (FOX)

• ceftiofur (TIO)

• ceftriaxone (AXO)

• chloramphenicol (CHL)

• ciprofloxacin (CIP)

• gentamicin (GEN)

• kanamycin (KAN)

• nalidixic acid (NAL)

• streptomycin (STR)

• tetracycline (TET)

• sulfisoxazole (SSS)

• trimethoprim/sulfamethoxazole (SXT)

The minimum inhibitory concentrations (MIC) and breakpoints were determined in accordance with guidelines established by the Clinical and Laboratory Standards Institute (CLSI) \[[@B16],[@B17]\].

Data analysis
=============

GraphPad Prism 5 software (GraphPad Software, Inc. La Jolla, CA) was used for statistical analysis.

Between 2002-2007, 578 *Shigella*isolates were received and confirmed by ProvLab. The overall distribution of species included: *S*. *sonnei*54.7% (n = 316); *S. flexneri*33.9% (n = 196); *S*. *boydii*7.6% (n = 44); *S*. *dysenteriae*3.8% (n = 22). Twenty nine *S. flexneri*and 79 *S. sonnei*were not archived (stored and cataloged); three *S. flexneri*could not be cultured; 15 *S. sonnei*belonged to four outbreaks and were removed as they had the same antibiogram as the index isolate for each outbreak (nine *S. sonnei*isolates in 2006 and six *S. sonnei*isolates in 2007). All but four *S. flexneri*and *S. sonnei*isolates were isolates from stool specimens; two *S*. *sonnei*isolates from blood, and two *S. flexneri*isolates were from blood and urine. Of the 386 *S. flexneri*and *S. sonnei*isolates, 74.9% (n = 289) were associated with international travel; 12.7% (n = 49) associated with domestic exposure within North America; 12.4% (n = 48) unknown travel history or origin of acquisition.

Rate calculations from Alberta population data were utilized to ensure no bias to study. The data set lacks a true denominator for all specimens received and tested. *S. flexneri*rates ranged from 0.70 to 1.21 per 100,000, and *S. sonnei*rates ranged from 1.10 to 1.98 per 100,000 per annum. The majority of travel cases for *S*. *flexneri*were from Central America (32.3% \[53/164\]), the Indian subcontinent (22.6% \[37/164\]) and North America (8.5% \[14/164\]). The majority of *S*. *sonnei*cases were from Central America (39.2% \[87/222\]), North America (15.8% \[35/222\]), and the Indian subcontinent (11.3% \[25/222\]).

Of the 196 *S. flexneri*isolates, as described above 164 were available for analysis, while 29 were not archived and 3 did not grow. The most common ST for *S. flexneri*was ST2 (37.8% \[62/164\]) with 40.3% (25/62) of the ST2 isolates originating from Central America. Of the *S*. *flexneri*isolates from the Indian subcontinent the two most common STs were ST2 (40.5% \[15/37\]) and ST6 (35.1% \[13/37\]). The most common phage type for *S. sonnei*was S1 (65.8% \[146/222\]) with (38.4% \[56/146\]of S1 isolates from Central America.

Only 1.2% (n = 2) *S. flexneri*and 8.1% (n = 18) *S. sonnei*isolates were pan-susceptible to all antibiotics tested. All *S. flexneri*isolates were susceptible to AMI, GEN, AMC, KAN, FOX, TIO, AXO. All the *S. sonnei*were resistant to AMP, CHL, NAL, STR, TET and SXT (Table [1](#T1){ref-type="table"}).

###### 

Travel history and frequency of antimicrobial resistance of *Shigella*isolates in Alberta, 2002-2007^A^

                                  North America   Central America   South America   Africa       Middle East   Indian subcontinent   Far East Asia   Unknown      Western Hemisphere   Eastern Hemisphere
  ------------------------------- --------------- ----------------- --------------- ------------ ------------- --------------------- --------------- ------------ -------------------- --------------------
  ***Shigella flexneri***         **N = 14**      **N = 53**        **N = 6**       **N = 27**   **N = 2**     **N = 37**            **N = 8**       **N = 17**   **N = 73**           **N = 74**
                                                                                                                                                                                       
                                  n(%)            n(%)              n(%)            n(%)         n(%)          n(%)                  n(%)            n(%)         n(%)                 n(%)
                                                                                                                                                                                       
  Streptomycin                    7(50)           30(57)            3(50)           12(44)       2(100)        32(86)                6(75)           14(82)       40(55)               52(70)
                                                                                                                                                                                       
  Ampicillin                      7(50)           39(74)            4(67)           22(81)       2(100)        23(62)                7(88)           14(82)       50(68)               54(73)
                                                                                                                                                                                       
  Trimethoprim-sulfamethoxazole   7(50)           21(40)            3(50)           17(63)       2(100)        26(70)                6(75)           14(82)       31(42)               51(69)
                                                                                                                                                                                       
  Sulfisoxazole                   7(50)           25(47)            3(50)           21(78)       2(100)        26(70)                8(100)          14(82)       35(48)               57(77)
                                                                                                                                                                                       
  Chloramphenicol                 8(57)           35(66)            4(67)           22(81)       2(100)        24(65)                6(75)           12(71)       47(64)               54(73)
                                                                                                                                                                                       
  Ciprofloxacin                   1(7)            0(0)              0(0)            0(0)         0(0)          7(19)^1^              0(0)            0(0)         1(1)                 7(9)
                                                                                                                                                                                       
  Nalidixic acid                  1(7)            0(0)              0(0)            0(0)         0(0)          21(57)                0(0)            3(18)        1(1)                 21(28)
                                                                                                                                                                                       
  Tetracycline                    13(93)          51(96)            6(100)          25(93)       2(100)        37(100)               6(75)           17(100)      70(96)               70(95)
                                                                                                                                                                                       
  ***Shigella sonnei***           **N = 35**      **N = 87**        **N = 14**      **N = 16**   **N = 2**     **N = 25**            **N = 12**      **N = 31**   **N = 136**          **N = 55**
                                                                                                                                                                                       
  Gentamicin                      0(0)            0(0)              1(7)            0(0)         0(0)          0(0)                  0(0)            1(3)         1(1)                 0(0)
                                                                                                                                                                                       
  Streptomycin                    34(97)          71(82)            7(50)           16(100)      2(100)        24(96)                10(83)          25(81)       109(80)              52(95)
                                                                                                                                                                                       
  Ampicillin                      8(23)           30(34)            9(64)           1(6)         0(0)          1(4)                  2(17)           19(61)       47(35)               4(7)
                                                                                                                                                                                       
  Amoxicillin/clavulanic acid     0(0)            0(0)              0(0)            0(0)         0(0)          0(0)                  0(0)            1(3)         0(0)                 0(0)
                                                                                                                                                                                       
  Ceftiofur                       0(0)            0(0)              0(0)            0(0)         0(0)          0(0)                  0(0)            2(6)         0(0)                 0(0)
                                                                                                                                                                                       
  Ceftriaxone                     0(0)            0(0)              0(0)            0(0)         0(0)          0(0)                  0(0)            2(6)         0(0)                 0(0)
                                                                                                                                                                                       
  Trimethoprim-sulfamethoxazole   26(74)          62(71)            14(100)         16(100)      2(100)        24(96)                11(82)          19(61)       99(73)               53(96)
                                                                                                                                                                                       
  Sulfisoxazole                   30(86)          64(74)            14(100)         15(94)       2(100)        25(100)               10(83)          24(77)       105(77)              52(95)
                                                                                                                                                                                       
  Chloramphenicol                 1(3)            0(0)              8(57)           0(0)         0(0)          1(4)                  1(8)            0(0)         9(7)                 2(4)
                                                                                                                                                                                       
  Ciprofloxacin                   0(0)            0(0)              0(0)            0(0)         0(0)          0(0)                  0(0)            0(0)         0(0)                 0(0)
                                                                                                                                                                                       
  Nalidixic acid                  4(11)           4(5)              0(0)            0(0)         0(0)          20(80)                0(0)            5(16)        8(6)                 20(36)
                                                                                                                                                                                       
  Tetracycline                    23(66)          57(66)            7(50)           15(94)       2(100)        25(100)               9(75)           14(45)       91(67)               51(93)

^A^Data for antimicrobial susceptible isolates are not shown

When median MICs were analyzed for all agents the following changes were identified as in Table [2](#T2){ref-type="table"}. For *S. flexneri*median MICs were within two dilutions for most agents over the study period. Exceptions were for the following agents; AMP (increase), CHL (increase), SXT (increase and following drop), and SSS (decrease). For *S. sonnei*, median MICs were within two dilutions for most agents over the study period with the following exceptions; exception of AMP (decrease).

###### 

Median MICs of antimicrobial agents in *S*. *flexneri*and *S*. *sonnei*per year.

                                               AMI   AMP     AMC   AXO         CHL     CIP          SXT         FOX   GEN   KAN      NAL   SSS       STR       TET     TIO
  ------------------- ------------------------ ----- ------- ----- ----------- ------- ------------ ----------- ----- ----- -------- ----- --------- --------- ------- -----------
  ***S. flexneri***   **Total per year (n)**                                                                                                                           
                                                                                                                                                                       
  2002                10                       4     2       2     \< = 0.25   0.5     \< = 0.015   \< = 0.12   2     1     \< = 8   1     \> 256    \< = 32   \> 32   \< = 0.12
                                                                                                                                                                       
  2003                28                       2     \> 32   8     \< = 0.25   \> 32   \< = 0.015   \> 4        2     0.5   \< = 8   1     \> 256    \> 64     \> 32   0.25
                                                                                                                                                                       
  2004                38                       2     \> 32   8     \< = 0.25   32      \< = 0.015   \> 4        2     0.5   \< = 8   1     \> 256    \> 64     \> 32   \< = 0.12
                                                                                                                                                                       
  2005                35                       2     \> 32   8     \< = 0.25   \> 32   \< = 0.015   \> 4        4     0.5   \< = 8   1     \> 256    64        \> 32   0.25
                                                                                                                                                                       
  2006                22                       2     \> 32   8     \< = 0.25   32      \< = 0.015   0.25        2     0.5   \< = 8   2     \> 256    64        \> 32   \< = 0.12
                                                                                                                                                                       
  2007                31                       2     \> 32   8     \< = 0.25   32      \< = 0.015   0.25        4     0.5   \< = 8   2     \< = 16   64        \> 32   \< = 0.12
                                                                                                                                                                       
                                                                                                                                                                       
                                                                                                                                                                       
  ***S. sonnei***     **Total per year (n)**                                                                                                                           
                                                                                                                                                                       
  2002                12                       2     32      4     \< = 0.25   4       \< = 0.015   \> 4        1     1     \< = 8   1     \> 256    \> 64     \> 32   0.25
                                                                                                                                                                       
  2003                27                       2     32      4     \< = 0.25   4       \< = 0.015   \> 4        1     1     \< = 8   1     \> 256    \> 64     \> 32   0.25
                                                                                                                                                                       
  2004                35                       2     2       4     \< = 0.25   4       \< = 0.015   \> 4        1     0.5   \< = 8   1     \> 256    \> 64     \> 32   0.25
                                                                                                                                                                       
  2005                60                       2     2       4     \< = 0.25   8       \< = 0.015   \> 4        2     1     \< = 8   1     \> 256    \> 64     \> 32   0.25
                                                                                                                                                                       
  2006                26                       2     2       2     \< = 0.25   4       \< = 0.015   \> 4        2     0.5   \< = 8   1     \> 256    \> 64     \> 32   0.25
                                                                                                                                                                       
  2007                19                       2     2       2     \< = 0.25   4       \< = 0.015   \> 4        2     0.5   \< = 8   2     \> 256    \> 64     \> 32   0.25

amikacin (AMI), amoxicillin/clavulanic acid (AMC), ampicillin (AMP), cefoxitin (FOX), ceftiofur (TIO), ceftriaxone (AXO), chloramphenicol (CHL), ciprofloxacin (CIP), gentamicin (GEN), kanamycin (KAN), nalidixic acid (NAL), streptomycin (STR), tetracycline (TET), sulfisoxazole (SSS), trimethoprim/sulfamethoxazole (SXT)

When data was combined for all years, the NAL and CIP resistance was 20.1% (33/164) and 14.9% (33/222) for *S. flexneri*and *S. sonnei*respectively. CIP resistance was identified only in *S. flexneri*isolates (4.9%, 8/164) when averaged over the six-year study period (Fisher\'s exact test, p = 0.001) (Figure [1a](#F1){ref-type="fig"} and [1b](#F1){ref-type="fig"}) CIP resistance in *S. flexneri*was not steady but instead was most evident in the years 2005, 2006, and 2007 (Figure [1a](#F1){ref-type="fig"}). Combined CIP and NAL resistance was related to travel to the Indian subcontinent for *S*. *flexneri*(84.8%, 28/37) and *S*. *sonnei*(80.0%, 20/25) (Fisher\'s exact test, p \< 0.0001). The proportion of antibiotic resistance was constant over six years except for *S. sonnei*, where AMP resistance decreased from 83% in 2002 to 11% in 2007 (p \< 0.0001, χ^2^= 36.52, df = 5) and NAL resistance increased from 0% in 2002 to 30% in 2007 (p = 0.0168, χ^2^= 13.82, df = 5).

![**Frequency of antimicrobial resistance of study isolates from Alberta 2002-2007: 1 a) *S. flexneri*(n = 164); and 1b) *S. sonnei*(n = 222)**.](1744-8603-6-20-1){#F1}

At the study onset, treatment guidelines suggested a fluoroquinolone for acute traveler\'s diarrhea regardless of travel location. It is possible that some CIP resistance was underestimated in 2002-2003 due to the smaller number of isolates tested. By 2009, treatment guidelines for acute traveler\'s diarrhea (outside of Latin America and Africa) suggested azithromycin or a fluoroquinolone \[[@B18],[@B19]\]. Data also suggests that azithromycin resistance may be emerging and resistance rates of 16% have been recently described in Bangladesh \[[@B20]\]. These studies indicate that travel to the Indian subcontinent, in patients returning to Western Canada with traveler\'s diarrhea should be determined to guide initial empiric treatment options; especially for severe infections because the association of *S*. *flexneri*and *S*. *sonnei*isolates from this region with fluoroquinolone and potential macrolide resistance \[[@B13],[@B21]\]. Although CIP resistance was described only in *S*. *flexneri*, we should remain vigilant for developing *gyrA*and *parC*mutations as well as the presence of plasmid mediated quinolone resistance determinants (PMQR) genes that may lead to increasing rates of CIP resistance in travel-related *Shigella*isolates which are beginning to emerge globally \[[@B4],[@B22]\].

There are multiple factors that may have lead to CIP and NAL resistance in *Shigella*species originating from the Indian subcontinent \[[@B21]\]. It is possible that part of this emerging resistance may be associated with the increasing dominance of specific STs or clones of *Shigella*. Both this study and other work have identified a dominance of *S*. *flexneri*STs 2 and 6 in isolates of Indian origin and cases of traveler\'s diarrhea associated with the Indian subcontinent \[[@B23]\]. One factor driving multi-drug resistance in the Indian subcontinent may be the emergence of specific clones within these dominant STs \[[@B24]\]. Therefore, the identification of clonal groups within Alberta strains may be a powerful tool for tracking the development of drug-resistance in *Shigella*isolates from future cases of traveler\'s diarrhea.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

SJD, CL, MA, CF, and ML participated in data analysis and interpretation of susceptibility and travel data, drafted and revised paper, and made follow-up revisions to submission. CL, CF performed susceptibility testing on isolates, and interpreted/analyzed this data. CL collated, analyzed, and interpreted travel history data. LS, BF participated in susceptibility testing on isolates, and reviewed paper. KS, DE collaborated for travel history data, and reviewed/edited paper. ML, CL conceived study design. All authors read and approved the final manuscript draft.

Acknowledgements
================

We thank M. Lovgren, S. Cook, R. Gordon and all the technologists and staff at the Provincial Laboratory for Public Health (Microbiology)(ProvLab) in Calgary and Edmonton, W. Demczuk and the National Microbiology Laboratory in Winnipeg, Manitoba for their support and contributions.

Data from this paper was presented in part as a poster at the 26th International Congress of Chemotherapy and Infection, Toronto, Ontario, 2009.
